CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo.
about
Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytesViraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trialToward a Rapid Production of Multivirus-Specific T Cells Targeting BKV, Adenovirus, CMV, and EBV from Umbilical Cord Blood.Engineering cord blood to improve engraftment after cord blood transplant.Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells.Validation of T-Track® CMV to assess the functionality of cytomegalovirus-reactive cell-mediated immunity in hemodialysis patientsFunctionally Active HIV-Specific T Cells that Target Gag and Nef Can Be Expanded from Virus-Naïve Donors and Target a Range of Viral Epitopes: Implications for a Cure Strategy after Allogeneic Hematopoietic Stem Cell TransplantationExtensive CD4 and CD8 T Cell Cross-Reactivity between Alphaherpesviruses.T cells for viral infections after allogeneic hematopoietic stem cell transplantAntigen-specific T cell therapies for cancer.Therapeutic strategies for cytomegalovirus in allogeneic hematopoietic cell transplantation.Optimal Practices in Unrelated Donor Cord Blood Transplantation for Hematologic Malignancies.Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation.Cytomegalovirus in hematopoietic stem cell transplant recipients - management of infection.Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma.Immunotherapy for transplantation-associated viral infections.Cytomegalovirus-Infected Cells Resist T Cell Mediated Killing in an HLA-Recognition Independent Manner.Direct measurement of T cell receptor affinity and sequence from naïve antiviral T cells.Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody-Activated Chimeric Antigen Receptor-Modified T Cells.MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults.Adoptive T cell therapy for the treatment of viral infections.Immunosequencing identifies signatures of cytomegalovirus exposure history and HLA-mediated effects on the T cell repertoire.Highlights from the Third Biennial Strategies for an HIV Cure Meeting: 14-16 November 2016, Bethesda, MD, USA.Virus-Specific T Cells for the Immunocompromised Patient.Considerations in T Cell Therapy Product Development for B Cell Leukemia and Lymphoma Immunotherapy.Cell and Gene Therapy for HIV Cure.Cord blood-derived T cells allow the generation of a more naïve tumor-reactive cytotoxic T-cell phenotype.HIV-Specific T Cells Generated from Naive T Cells Suppress HIV In Vitro and Recognize Wide Epitope Breadths.HIV-Specific, Ex Vivo Expanded T Cell Therapy: Feasibility, Safety, and Efficacy in ART-Suppressed HIV-Infected Individuals
P2860
Q29393780-BA16E2D0-8F82-4933-8A1B-101CAB4268ACQ33429827-7220E438-D492-4C53-AD42-FE36B01FED62Q33633262-3728955A-E715-497B-8836-A1F8A35315E0Q33766995-DF550C2B-FD4A-42F4-9CC6-A4DB0D1D79E6Q36276185-937AE6B6-30CB-401F-8289-3C4BC6DBEE7BQ36299933-A407A8F8-7FDD-4D78-A2A0-95EA70814894Q36578672-DBE7774A-4CE6-4DE0-B649-E6661E84E241Q36601101-808229C6-17F1-4015-AD83-3E899BB86220Q37058107-AD9ECFC8-05B6-405F-B123-68B1F65E9E81Q38544740-8EDDE4D1-8706-45D1-9D06-9144E093C5ABQ38617612-3A4733F3-F7CD-4654-B369-112ECE52B67CQ38747929-7B16746E-C34A-4F53-8C20-1E8023046B4EQ38797660-8D371C35-FE06-402C-B91E-2B99B1CA4DF9Q38802522-26D8F7FD-5FDF-4DFC-9B09-42D83C85AB6CQ38803361-67B05072-0F7D-463D-A341-EC40AD73BCB7Q39382670-B6DE0B45-E547-4574-85E7-2664B50DA2DAQ39634413-0FEBBA7B-85CB-4B6B-BB5C-4179BDB916EFQ39978090-BD21C9F8-0017-4F2B-904E-3A56AF65FAFDQ40183378-51F40B8B-6D5E-4A78-8DBA-F8A6BCC844DDQ40497816-78BA2431-3CE2-4262-8D06-A01B40FDCA17Q40895824-A2301A59-9AEA-406A-AE8A-721AC5A58324Q41979810-BAACEC6C-4747-40F0-9366-007B055ED742Q42318283-64CFA874-82F1-4E74-AD8A-C47DE72F7DACQ42654381-1D8F6B92-C20D-419F-9E1A-1B870CAAA0C0Q45870279-29363B92-12B7-4B6A-A5ED-8F2807AD2FD8Q47236016-3E01DBD0-2319-4943-9EF2-A81A50B0BA30Q50098673-4E26FBB7-2A33-42D6-9910-D414ED41362CQ52803378-5DE0E41E-AF95-46B1-B9C2-2659F80D1BECQ57039737-C5702912-659D-452B-8E1E-530D2787D3B8
P2860
CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
CMV-specific T cells generated ...... and may be protective in vivo.
@ast
CMV-specific T cells generated ...... and may be protective in vivo.
@en
type
label
CMV-specific T cells generated ...... and may be protective in vivo.
@ast
CMV-specific T cells generated ...... and may be protective in vivo.
@en
prefLabel
CMV-specific T cells generated ...... and may be protective in vivo.
@ast
CMV-specific T cells generated ...... and may be protective in vivo.
@en
P2093
P2860
P1476
CMV-specific T cells generated ...... and may be protective in vivo.
@en
P2093
A John Barrett
C Russell Cruz
Caridad A Martinez
Catherine M Bollard
Cliona M Rooney
Daniel C Douek
Elizabeth J Shpall
Gail Demmler-Harrison
Helen E Heslop
P2860
P304
P356
10.1126/SCITRANSLMED.AAA2546
P407
P577
2015-04-01T00:00:00Z